Morning Medical with Dr. Chow
A daily update covering the latest medical & health news from around the world using artificial intelligence. Doctor Chi-Ming Chow is a family physician, general internist, and cardiologist. He is also a Professor of Medicine at the University of Toronto.
Sulfonylureas Risks, Brain Aging in COVID, and Painkiller Shortages in Canada
In this episode, Dr. Chi-Ming Chow delves into the cardiovascular risks associated with sulfonylureas in Type 2 Diabetes, presenting recent study findings that compare these drugs with DPP4 inhibitors and their clinical implications. An editorial perspective offers insights into the affordability of treatments, choices, and study methodology. Dr. Chow updates listeners on the resident doctors' strike in England and explores research on accelerated brain aging during the COVID-19 pandemic. He questions the necessity of eating three meals a day and shares tips for enhancing daily walks. The episode also addresses a nationwide shortage of prescription painkillers in Canada, concluding with closing remarks.
Key Points
- The latest study reveals that glipizide, a sulfonylurea, is linked to a 13% relative increase in cardiovascular risk for patients with Type 2 Diabetes compared to DPP4 inhibitors.
- A UK study found that the COVID-19 pandemic period was associated with accelerated brain aging, regardless of infection status, highlighting the significant impact of pandemic-related stressors on neurological health.
- Canada is experiencing a nationwide shortage of prescription painkillers containing acetaminophen with codeine or oxycodone, prompting pharmacists to limit dispensed amounts and seek alternative pain management options.
Chapters
| 0:00 | |
| 0:21 | |
| 2:09 | |
| 3:23 | |
| 6:31 | |
| 10:19 | |
| 14:34 | |
| 20:32 | |
| 22:51 |
Transcript
Loading transcript...
- / -